Shots:
The P-IIa trial evaluates tegoprubart in 54 patients with ALS at 13 sites in the US & Canada. The trial met its 1EPs of safety & tolerability with no drug-related serious AEs, ADAs were of low titer and did not impact tegoprubart drug levels
At doses of 4 & 8mg/kg, target engagement was dose-dependent, ALS associated pro-inflammatory biomarkers were observed and significantly reduced in a dose dependent manner, pro-inflammatory biomarkers reduced included biomarkers also associated with IgAN and kidney allograft transplant rejection
Additionally, target engagement & pro-inflammatory biomarker reduction were linked to a trend in disease progression slowing over ALS PRO-ACT database
Ref: Eledon | Image: Eledon
